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A	Central	Role	for	LRRK2	in	Idiopathic	Parkinson	Disease	
	
Summary:	Wildtype	LRRK2	is	activated	in	dopamine	neurons	in	idiopathic	Parkinson	disease	and	plays	a	
pathogenic	role	in	the	disease.	
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SUMMARY	
	
Abnormally	increased	kinase	activity	due	to	mutations	in	the	leucine	rich	repeat	kinase	2	(LRRK2)	gene	
is	the	cause	of	Parkinson	disease	(PD)	in	about	3-4%	of	people	with	the	disease.	We	now	show	that,	in	
the	brains	of	individuals	with	idiopathic	PD,	LRRK2	kinase	activity	is	aberrantly	increased	in	vulnerable	
dopamine	 neurons	 by	 oxidative	 mechanisms	 involving	 α-synuclein	 and	mitochondrial	 impairment	 –	
and	 this	 causes	 endolysosomal	 dysfunction	 and	 accumulation	 of	 phosphorylated	 α-synuclein.	 Thus,	
independent	of	mutation,	activation	of	LRRK2	kinase	activity	contributes	importantly	to	pathogenesis,	
suggesting	inhibition	of	LRRK2	kinase	activity	will	be	useful	for	the	majority	of	PD	patients.	
	
	
	
	
	
ABSTRACT	
	
Missense	mutations	in	leucine-rich	repeat	kinase	2	(LRRK2)	cause	familial	Parkinson	disease	(PD);	
however,	the	role	of	wildtype	LRRK2	in	idiopathic	PD	(iPD)	is	unclear.	Here,	we	show	that	wildtype	
LRRK2	kinase	activity	is	selectively	enhanced	in	substantia	nigra	dopamine	neurons	in	idiopathic	PD	and	
two	different	animal	models	of	the	disease.		This	occurs	through	ROS	signaling,	resulting	in	
phosphorylation	of	the	LRRK2	substrate	Rab10	and	other	downstream	consequences	including	
abnormalities	of	mitochondrial	protein	import	and	lysosomal	function.		Overall,	our	work	shows	that,	
independent	of	mutations,	wildtype	LRRK2	plays	a	key	role	in	idiopathic	PD.		LRRK2-directed	
therapeutics	may	therefore	be	useful	for	most	people	with	PD.	
		
	
	
	
	
	
	
	
	
	 	
INTRODUCTION	
Parkinson’s	disease	(PD)	is	a	common	neurodegenerative	disease	that	results	in	motor	impairment,	
cognitive	and	psychiatric	symptoms	and	autonomic	dysfunction	(1).	While	numerous	gene	mutations	
are	known	to	cause	familial	PD,	about	90%	of	cases	are	“idiopathic”	(iPD).	LRRK2	missense	mutations	
are	the	most	common	cause	of	autosomal	dominant	PD,	and	may	account	for	about	3%	of	cases	
overall	(2,	3).	The	LRRK2	locus	also	contains	a	risk	factor	for	iPD	(4),	but	the	role	of	LRRK2	in	typical	iPD	
is	unknown.	It	is	generally	believed	that	the	common	missense	mutations	in	LRRK2	confer	a	toxic	gain-
of-function	and	increased	LRRK2	kinase	activity	has	been	strongly	implicated	in	pathogenesis	(5).	
Among	the	kinase	substrates	of	LRRK2	are	a	subset	of	the	Rab	GTPases,	including	Rab10,	which	has	
been	implicated	in	maintenance	of	endoplasmic	reticulum,	vesicle	trafficking	and	autophagy	(6).	
LRRK2-induced	phosphorylation	of	Rab10	inhibits	its	function	by	preventing	binding	to	Rab	GDP-
dissociation	inhibitor	factors	necessary	for	membrane	delivery	and	recycling.	As	such,	aberrantly	
enhanced	LRRK2	kinase	activity	is	likely	associated	with	reduced	activity	of	Rab10	and	its	effectors.	
	
Assessment	of	the	kinase	activity	state	of	LRRK2	under	various	conditions	has	been	somewhat	
cumbersome,	although	there	appears	to	be	a	growing	consensus	that	autophosphorylation	at	Ser1292	
correlates	with	activity	(7,	8).	Phosphoserine1292	(pS1292)	has	generally	been	detected	by	western	
blotting	rather	than	immunocytochemistry,	which	limits	anatomical	or	cellular	resolution.	LRRK2	is	
believed	to	be	a	rather	low-abundance	protein,	and	efforts	to	detect	it	immunocytochemically	
sometimes	rely	on	high	antibody	concentrations,	which	may	reduce	specificity.	This	problem	may	be	
compounded	for	pS1292	when	only	a	fraction	of	the	total	(small)	pool	of	LRRK2	is	phosphorylated.	The	
activity	of	LRRK2	is	also	regulated	by	its	interaction	with	14-3-3	proteins,	whose	binding	to	LRRK2	
requires	phosphorylation	at	LRRK2	serine	residues	910	and	935	(9,	10),	which	are	not	
autophosphorylation	sites.	Although	the	binding	of	LRRK2	to	14-3-3	protein	is	associated	with	reduced	
kinase	activity	(11),	this	interaction	can	be	disrupted	by	oxidative	stressors,	including	H2O2	(12).	The	
interaction	between	LRRK2	and	14-3-3	has	generally	been	assessed	by	co-immunoprecipitation.	A	
critical	barrier	to	understanding	the	role	of	LRRK2	in	iPD	has	been	the	absence	of	a	practical,	sensitive,	
high-resolution	assay	for	its	activation	state.	
	
We	have	developed	and	validated	novel	proximity	ligation	(PL)	assays	with	excellent	anatomical	
resolution	that	can	rapidly	provide	information	regarding	activation	state,	cellular	localization	and	
physiological	regulators	of	LRRK2.	The	assay	is	based	on	(i)	S1292	phosphorylation	and	(ii)	dissociation	
of	14-3-3	from	LRRK2.	Using	this	and	other	assays,	we	provide	evidence	that	LRRK2	is	activated	
oxidatively	by	mitochondrial	impairment	or	α-synuclein	overexpression	and	that	it	plays	a	central	role	
in	iPD	pathogenesis	by	regulating	autophagy	and	pSer129-α-synuclein	levels.	
	
	 	
RESULTS	
Assay	development	and	validation	
As	a	LRRK2	autophosphorylation	site,	pSer1292	reflects	the	activity	of	LRRK2	per	se.	As	such,	we	
developed	a	proximity	ligation	assay	to	amplify	the	signal	and	increase	the	specificity	of	an	antibody	
recognizing	the	pSer1292	epitope	of	the	protein.	For	the	PL	assay,	we	paired	the	anti-pSer1292	
antibody	with	a	validated	antibody	directed	against	an	epitope	in	the	COR	domain	of	the	protein.	In	
this	way,	the	signal	of	the	anti-pSer1292	antibody	was	amplified	and	detected	only	if	it	was	in	
proximity	to	the	anti-COR	domain	antibody	(i.e.,	specific	LRRK2	pSer1292	signals	were	amplified,	
whereas	potential	signals	from	non-specific	or	off-target	antibody	binding	were	filtered	out	by	the	PL	
assay).	A	second	PL	assay	assessed	the	interaction	between	LRRK2	and	14-3-3,	whose	binding	to	LRRK2	
is	associated	with	reduced	activity.	Thus,	the	PL	assays	were	designed	such	that	LRRK2	activity	should	
be	associated	with	a	strong	pSer1292	signal	and	a	weak	14-3-3	signal;	conversely,	when	LRRK2	is	
inactive	there	should	be	little	pSer1292	signal	and	a	robust	14-3-3	signal.		
	
To	validate	the	assays,	we	used	wildtype	(WT),	LRRK2G2019S/G2019S	and	LRRK2-/-	human	embryonic	
kidney-	(HEK-)	293	cells,	obtained	by	CRISPR/Cas9	gene	editing.	In	WT	cells,	there	was	little	pSer1292	
signal	and	a	strong	14-3-3	PL	signal	(figure	1A,	B,	D,	E).	The	G2019S	mutation	is	known	to	cause	
increased	LRRK2	kinase	activity	(5,	6).	Accordingly,	in	LRRK2G2019S/G2019S	cells,	there	was	a	bright	
pSer1292	signal	and	loss	of	the	14-3-3	interaction.	No	signal	in	either	PLA	was	seen	in	cells	lacking	
LRRK2	(figure	1A,	B,	D,	E),	further	establishing	the	specificity	of	the	assays.	The	small	GTPase,	Rab10,	
has	recently	been	shown	to	be	directly	phosphorylated	at	Thr73	by	LRRK2	(6).	Using	a	specific	pThr73-
Rab10	antibody,	we	found	low	levels	of	phosphorylated	Rab10	in	WT	cells,	and	much	higher	levels	in	
LRRK2G2019S/G2019S	cells,	in	keeping	with	increased	kinase	activity	of	the	mutant	protein	(figure	1A,	C,	D).	
After	assay	development,	validation	included	blinded	analysis	and	correct	identification	of	all	3	cell	
lines	with	these	assays	alone.	Using	the	selective	LRRK2	kinase	inhibitors,	GNE-7915	and	MLi-2	(13),	in	
dose-response	studies,	we	found	that	LRRK2	activation	state,	assessed	by	pSer1292	PL	signal,	
correlated	closely	with	phosphorylation	of	its	substrate,	Rab10	(figure	1F,	G).	We	next	looked	at	LRRK2	
activation	state	in	patient-derived	lymphoblastoid	cell	lines.	Relative	to	cells	derived	from	a	healthy	
age-matched	control,	in	a	LRRK2	G2019S	mutation	carrier,	there	was	marked	elevation	of	the	pSer1292	
signal	and	titration	with	the	selective	LRRK2	kinase	inhibitor,	GNE-7915,	dose-dependently	reduced	the	
pSer1292	PL	and	pThr73-Rab10	signals	in	parallel	(figure	1H).		
	
To	summarize,	basal	kinase	activity	of	endogenous	WT	LRRK2,	assessed	by	pSer1292	PL	and	pThr-
Rab10	immunoreactivity	was	low.	This	was	associated	with	a	strong	14-3-3	PL	signal,	suggesting	a	
significant	interaction	with	14-3-3	protein.	In	cells	harboring	the	pathogenic	G2019S	mutation,	LRRK2	
was	highly	activated	(strong	pSer1292	PL	signal	and	elevated	levels	of	Rab10	phosphorylation)	and	
there	was	loss	of	the	14-3-3	interaction.	LRRK2	activation	as	evaluated	by	pSer1292	PL	and	pThr-Rab10	
immunoreactivity,	was	reversed	by	the	LRRK2	kinase	inhibitors,	GNE-7915	and	MLi-2,	at	appropriate	
concentrations.		
	
Endogenous,	wildtype	LRRK2	is	activated	in	idiopathic	PD	
Conventional	assays	of	LRRK2	activity	often	rely	on	overexpression,	and	they	require	substantial	
amounts	of	tissue,	lack	cellular/anatomical	resolution,	and	cannot	be	performed	in	previously	fixed	
tissue.	In	contrast,	our	assays	can	assess	the	activation	state	of	endogenous	LRRK2	on	a	cell-by-cell	
basis	using	fixed	cells	or	tissue.	In	this	context,	we	measured	pSer1292	PL	and	pThr73-Rab10	by	
quantitative	confocal	immunofluorescence	in	sections	of	substantia	nigra	from	7	individuals	dying	with	
iPD	and	from	8	controls	matched	for	age	and	postmortem	interval.	In	nigrostriatal	dopamine	neurons	
from	healthy	controls,	there	were	very	low	basal	levels	of	pSer1292	PL	and	pThr73-Rab10	
immunoreactivity	signal	and	a	strong	14-3-3	PL	signal	(figure	2).	In	contrast,	the	remaining	dopamine	
neurons	from	the	iPD	cases	showed	about	a	6-fold	increase	in	pSer1292	PL	(p<0.0002,	two-tailed,	
unpaired	t-test;	p<0.002	with	Welch’s	correction	for	unequal	variances),	and	this	was	associated	with	a	
4-fold	increase	in	phosphorylation	(pThr73)	of	the	LRRK2	substrate	Rab10	(p<0.0002).	The	increase	in	
LRRK2	activation	state	in	iPD	dopamine	neurons	corresponded	to	a	5-fold	decrease	in	the	14-3-3	PL	
signal	(p<0.0001;	p<0.0004	with	Welch’s	correction).	Thus,	there	is	evidence	that	endogenous	WT	
LRRK2	is	activated	in	dopamine	neurons	in	iPD,	and	this	is	associated	with	increased	substrate	
phosphorylation.		
	
In	addition	to	neuronal	expression,	LRRK2	has	also	been	associated	with	microglia	(14).	We	found	
detectable	levels	of	pS1292	PL	signal	in	nigral	microglia	in	controls	(figure	S1A,	B),	and	the	signal	was	
more	than	doubled	in	microglia	from	iPD	cases	(p<0.0005,	two-tailed,	unpaired	t-test).	
	
WT	LRRK2	activation	is	reproduced	in	mitochondrial	and	α-synuclein	models	of	PD	
Mitochondrial	impairment	and	α-synuclein	accumulation/aggregation	have	been	strongly	implicated	in	
PD	pathogenesis	(15).	Therefore,	we	tested	whether	LRRK2	is	similarly	activated	in	rat	models	based	on	
these	mechanisms.	First,	we	used	the	rotenone	model	of	PD,	which	has	been	shown	to	reproduce	or	
even	predict	pathological	and/or	pathogenic	features	of	the	disease	(16).	Using	substantia	nigra	
sections	from	rotenone-treated	rats	that	had	reached	behavioral	endpoint	(severe	parkinsonism	after	
10-14	days),	we	found	a	10-fold	increase	in	pSer1292	PL	signal	in	nigrostriatal	dopamine	neurons	
compared	to	vehicle-treated	controls	(p<0.0001,	unpaired,	2-tail	t-test)	(figure	3A-C).	In	these	animals,	
there	was	a	dramatic	loss	of	the	14-3-3	PL	signal	(p<0.0001,	unpaired,	2-tail	t-test)	similar	to	the	
changes	we	observed	in	human	brain.	As	in	iPD	brains,	we	found	detectable	pS1292	PL	signal	in	control	
microglia	(figure	S1C,D),	and	the	signal	was	more	than	doubled	after	rotenone	treatment	(p<0.05,	
unpaired,	2-tail	t-test).	To	determine	whether	LRRK2	activation	occurs	prior	to	neurodegeneration,	we	
examined	tissue	from	animals	that	received	only	1	or	5	days	of	rotenone,	time	points	at	which	we	
detect	no	degeneration	of	the	nigrostriatal	neurons	(figure	S2).	After	a	single	dose	of	rotenone,	
pSer1292	PL	signal	was	increased	5-fold	relative	to	vehicle	treatment	(p<0.0001,	ANOVA	with	
Bonferroni	correction),	and	after	5	daily	doses,	the	PL	signal	was	increased	6-fold	(p<0.0001).	These	
results	indicate	that	mitochondrial	impairment	can	lead	to	activation	of	LRRK2	well	before	there	is	any	
neurodegeneration.		
	
α-Synuclein	accumulation	and	Lewy	pathology	are	hallmarks	of	PD.	Elevated	levels	of	WT	α-synuclein	
may	cause	PD,	and	several	groups	have	used	viral	vector-mediated	overexpression	of	α-synuclein	as	a	
model	of	PD	(17).	Here,	we	used	adeno-associated	virus	type	2	(AAV2)-mediated	overexpression	of	
wildtype	human	α-synuclein	(hSNCA)	injected	unilaterally	into	substantia	nigra	pars	compacta	to	
induce	slowly	progressive	neurodegeneration.	Six	weeks	after	vector	injection,	when	degeneration	is	
ongoing,	remaining	nigrostriatal	neurons	showed	a	marked	10-fold	increase	in	pSer1292	PL	signal	
compared	to	the	contralateral,	uninjected	hemisphere	(p<0.0001,	paired	2-tail	t-test)	–	and	there	was	
a	concomitant	loss	of	the	14-3-3	PL	signal	(p<0.0001)	(figure	3D-F).		
	
Both	rotenone	treatment	and	AAV2-mediated	α-synuclein	overexpression	lead	to	oligomerization	of	α-
synuclein,	as	well	as	accumulation	of	Ser129-phosphorylated	α-synuclein	(18,	19).	We	recently	
identified	soluble	oligomers	and	pSer129-α-synuclein	as	specific	forms	of	α-synuclein	that	have	
deleterious	effects	on	mitochondrial	protein	import	machinery	and	which	cause	mitochondrial	
impairment	(15).	In	analogous	fashion,	when	SNCA-/-	cells	were	treated	with	exogenous	soluble	
oligomers	of	α-synuclein	(400	nM	monomer	equivalent)	for	24	hours,	there	was	marked	activation	of	
endogenous	WT	LRRK2	with	increased	pSer1292	and	loss	of	14-3-3	PL	signals	(figure	S3)	(p<0.0001,	
ANOVA	with	Bonferroni	correction).	Treatment	with	monomeric	α-synuclein	did	not	activate	LRRK2.	
	
Both	rotenone	treatment	and	elevated	α-synuclein	increase	formation	of	reactive	oxygen	species	(ROS)	
and	both	insults	activate	WT	LRRK2,	which	raises	the	possibility	that	it	is	secondary	generation	of	ROS	
that	actually	activates	LRRK2.	To	test	directly	whether	ROS	can	activate	LRRK2,	we	treated	WT	cells	
with	H2O2	(figure	4A,	B).	Treatment	with	H2O2	dose-dependently	(50	nM	–	5	µM)	activated	the	
pSer1292	PL	signal	(p<0.0001	vs.	control	for	all	H2O2	doses;	1-way	ANOVA	with	Bonferroni	correction)	
and	increased	phosphorylation	of	its	substrate,	Rab10	(p<0.0001	for	all	doses	above	50	nM	H2O2).	The	
antioxidant,	α-tocopherol,	blocked	H2O2	activation	of	the	pSer1292	signal	(p<0.0001)	and	Rab10	
phosphorylation	(p<0.0001).	
	
Further	evidence	of	oxidative	activation	of	LRRK2	resulted	from	study	of	endogenous	NADPH	oxidase	2	
(NOX2).	As	in	vivo,	we	found	that	rotenone	treatment	of	WT	HEK-293	cells	caused	an	increased	
pSer1292	PL	signal	and	Rab10	phosphorylation	(figure	4C-E).	Although	rotenone	may	cause	
mitochondrial	ROS	formation,	mitochondrially-derived	ROS	may	also	activate	NOX2	in	a	process	known	
as	ROS-induced	ROS	release,	which	can	feed	forward	to	amplify	ROS	production	(20,	21).	We	found	
that	co-treatment	with	rotenone	plus	the	specific	NOX2	inhibitor	peptide,	Nox2ds-tat	(22),	blocked	
rotenone’s	effects	on	LRRK2	activation	and	phosphorylation	of	its	substrate	(p<0.0001,	1-way	ANOVA	
with	Bonferroni	correction).	Thus,	NOX2-generated	superoxide	appears	to	be	important	in	activating	
LRRK2.		
	
In	vivo	treatment	with	a	LRRK2	kinase	inhibitor	blocks	rotenone-induced	activation	of	nigrostriatal	
LRRK2	and	has	beneficial	effects	on	pSer129-α-synuclein	levels	and	markers	of	autophagy	&	
lysosomes.		
The	rotenone	model	of	PD	reproduces	many	features	of	the	human	disease,	including	accumulation	of	
pSer129-α-synuclein,	impairment	of	autophagy,	reduced	mitochondrial	protein	import	(15),	and	now,	
activation	of	endogenous	WT	LRRK2	in	nigrostriatal	dopamine	neurons.	To	determine	whether	
systemic	treatment	with	a	brain-penetrant	LRRK2	inhibitor	could	block	rotenone-induced	LRRK2	
activation,	and	to	survey	some	of	the	potential	downstream	effects	of	LRRK2	activation,	rats	were	
treated	for	5	days	with	rotenone	(2.8	mg/kg/day,	i.p.)	with	or	without	concomitant	PF-360	(10	mg/kg	
p.o.	twice	daily),	a	highly	selective	LRRK2	kinase	inhibitor	(23,	24).	This	PF-360	dosing	regimen	results	in	
a	pharmacokinetic	profile	in	which	an	IC90	concentration	in	brain	is	achieved	for	15	hours	daily	and	an	
IC50	concentration	is	achieved	for	a	full	24	hours.		
	
In	a	new	cohort	of	rats	treated	with	rotenone	for	5	days,	there	was	a	marked	increase	in	pSer1292	PL	
signal	in	nigrostriatal	neurons,	which	was	associated	with	an	increase	in	phosphorylation	of	Rab10	
(figure	5A-C).	Co-treatment	with	PF-360	effectively	blocked	the	rotenone-induced	activation	of	LRRK2	
(p<0.0001,	two-way	ANOVA,	Sidak’s	correction)	and	phosphorylation	of	Rab10	(p<0.0001).	Thus,	the	
pSer1292	PL	assay	provided	an	ex	vivo	assay	of	target	(LRRK2)	engagement	by	PF-360,	which	was	
corroborated	by	measurement	of	pThr73-Rab10.		
	
We	reported	previously	that	chronic	rotenone	treatment	(10-14	days)	leads	to	elevated	levels	of	
pSer129-α-synuclein	(15).	Here	we	found	that	the	rats	treated	for	only	5	days	also	accumulated	
pSer129-α-synuclein,	and	co-treatment	with	PF-360	prevented	this	accumulation	(figure	5D,	E).	The	
mechanism	by	which	pSer129-α-synuclein	accrues	in	response	to	rotenone	is	uncertain,	but	it	has	been	
suggested	that	phosphorylation	of	α-synuclein	at	ser129	targets	the	protein	for	degradation	by	
autophagy	(25,	26).	Both	chaperone-mediated	autophagy	(CMA)	and	macroautophagy	play	roles	in	α-
synuclein	degradation	(27,	28).	Therefore,	we	assessed	a	marker	for	CMA,	Lamp2A,	which	is	located	on	
lysosomes,	and	another	marker,	Lamp1,	which	may	label	late	endosomes,	autolysosomes	or	lysosomes.	
There	were	abundant	Lamp2A	and	Lamp1	punctae	in	dopamine	neurons	from	vehicle	treated	rats,	
which	were	dramatically	lost	after	rotenone	treatment,	and	preserved	by	co-treatment	with	PF-360	
(figure	6A-E).	Together,	these	results	indicate	that	there	is	early	profound	impairment	of	CMA	and	
lysosomal	function	which	is	downstream	of	LRRK2	kinase	activity.	Additionally,	these	results	suggest	
that	pSer129-α-synuclein	accumulates	in	rotenone	treated	rats	because	of	LRRK2-induced	CMA	and	
lysosomal	dysfunction	–	and	LRRK2	kinase	inhibition	prevents	this.	To	complement	these	
pharmacological	studies,	we	examined	the	effects	of	rotenone	on	pSer129-α-synuclein	in	WT	and	
LRRK2-/-	HEK	cells.	As	in	vivo,	we	found	that	rotenone	treatment	caused	accumulation	of	pSer129-α-
synuclein	in	WT	cells;	however,	there	was	no	such	accumulation	in	the	LRRK2	null	cells	(Figure	S4),	
thereby	providing	further	evidence	that	buildup	of	pSer129-α-synuclein	is	LRRK2-dependent.	Moreover,	
the	rotenone-induced	increase	in	pSer129-α-synuclein	in	WT	cells	was	effectively	blocked	by	PF-360	to	
the	same	extent	as	in	LRRK2-/-	cells,	confirming	the	specificity	of	the	PF-360	effect.	
	
Similar	to	rotenone-treated	rats,	there	was	a	dramatic	loss	of	Lamp1	puncta	in	human	brain	specimens	
from	individuals	with	iPD	(p<0.001,	unpaired	2-tail	t-test)	and	this	was	accompanied	by	an	
accumulation	of	the	autophagy	cargo	receptor,	p62/SQSTM1	(p<0.03),	into	Lewy	bodies,	indicating	
autophagic	and	lysosomal	dysfunction	(figure	6F,	G).	As	reported	by	many	other	groups,	and	as	seen	in	
rotenone-treated	rats,	there	is	accumulation	of	pSer129-α-synuclein	in	substantia	nigra	in	iPD.		
	
In	vitro	experiments	have	shown	that	pSer129-α-synuclein	binds	to	TOM20	and	inhibits	mitochondrial	
protein	import;	however,	this	has	not	been	examined	directly	in	human	brain	or	in	the	rotenone	rat.	
Examination	of	human	iPD	brains	(figure	7A,B)	revealed	a	marked	increase	of	pSer129-α-synuclein-
TOM20	PL	signal	(p<0.0001,	unpaired,	2-tail	t-test),	indicating	that	accumulation	of	this	specific	form	of	
α-synuclein	has	toxic	consequences	in	terms	of	mitochondrial	protein	import.	Similarly,	in	the	rotenone	
rats	(figure	7C-E),	the	increased	pSer129-α-synuclein	we	found	at	5	days	was	associated	with	its	
binding	to	TOM20,	measured	as	a	strong	pSer129-α-synuclein-TOM20	PL	signal	(p<0.0001,	2-way	
ANOVA	with	Bonferroni	correction),	as	well	as	reduced	levels	and	redistribution	of	the	imported	
complex	I	subunit,	Ndufs3,	from	mitochondria	to	cytosol	(P<0.0001).	Co-treatment	with	PF-360	
prevented	the	elevation	in	pSer129-α-synuclein	levels	(figure	5E)	and,	as	a	result,	there	was	little	
binding	to	TOM20	(p<0.0001	vs	rotenone	alone),	and	there	was	preservation	of	normal	levels	and	
mitochondrial	localization	of	Ndufs3	(figure	7C,E).	Thus,	both	the	accumulation	of	pSer129-α-synuclein	
and	its	toxic	consequences	appear	to	be	downstream	of	LRRK2	kinase	activity.		
	 	
DISCUSSION	
Development	of	a	new	assay	allowed	us	to	show	that	endogenous	WT	LRRK2	is	activated	in	
nigrostriatal	dopamine	neurons	in	iPD	–	and	this	can	be	reproduced	in	rodent	models	of	the	disease.	
While	our	new	assay	does	not	measure	activity	per	se,	it	provides	a	snapshot	of	relative	LRRK2	
activation	state	and	does	so	with	a	cellular	level	of	resolution	(e.g.,	in	dopamine	neurons	and	microglia).	
The	assay	was	validated	(i)	by	using	gene-edited	cells,	(ii)	by	demonstrating	that	the	readout	of	LRRK2	
activation	state	(pSer1292	PL	signal)	correlates	with	substrate	(Rab10)	phosphorylation	levels,	and	(iii)	
by	showing	that	both	the	pSer1292	PL	and	pThr73-Rab10	signals	respond	appropriately	and	in	parallel	
to	3	structurally	distinct	LRRK2	kinase	inhibitors	(GNE-7915,	MLi-2	and	PF-360).	Consistent	with	our	
results,	others	showed	recently,	by	means	of	immunoblotting,	that	the	phosphorylation	state	of	LRRK2	
(at	Ser935)	correlates	with	Rab10	phosphorylation	in	dose-response	studies	using	PF-360	(23).		
	
The	finding	that	treatment	of	G2019S	mutant	engineered	or	patient-derived	cells	with	kinase	inhibitors	
blocks	the	pSer1292	PL	signal	indicates	that	this	readout	is	readily	reversible.	Thus,	the	relative	degree	
of	LRRK2	activation	detected	reflects	the	physiological	state	of	LRRK2	in	the	cell	or	tissue	at	the	specific	
time	of	fixation.	Additionally,	the	ease	with	which	inhibitor	dose-response	relationships	can	be	
assessed	suggests	the	assay	can	provide	a	quantitative	measure	of	target	(LRRK2)	engagement.		
	
Recent	work	from	West	and	colleagues	showed	that	genetic	ablation	or	pharmacological	kinase	
inhibition	of	endogenous	WT	LRRK2	reduced	the	toxicity	of	AAV2-hSNCA	injected	into	substantia	nigra,	
suggesting	a	possible	role	of	LRRK2	in	α-synuclein	toxicity	(29,	30).	Implicit	in	such	a	conclusion	is	the	
assumption	that	WT	LRRK2	kinase	must	be	active	in	nigrostriatal	neurons	under	these	experimental	
conditions;	however,	this	has	been	difficult	to	demonstrate	with	conventional	assays.	Consistent	with	
this	supposition,	we	found	that	AAV2-hSNCA	(as	used	by	West	and	colleagues)	activates	LRRK2	in	
nigrostriatal	neurons.	In	this	context,	our	findings	indicate	that	LRRK2	is	activated	in	the	vulnerable	
dopamine	neurons	in	human	iPD	and	suggest	that	endogenous	WT	LRRK2	may	play	a	role	pathogenesis.		
	
Our	assay	allows	relatively	facile	assessment	of	physiological	regulators	of	LRRK2	activity.	In	cell	culture,	
we	showed	that	low	concentrations	of	oligomeric,	but	not	monomeric,	α-synuclein	activate	LRRK2.	We	
recently	reported	that	oligomeric,	but	not	monomeric,	α-synuclein	binds	to	TOM20,	impairs	
mitochondrial	protein	import,	and	causes	mitochondrial	dysfunction	and	aberrant	ROS	production	(15).	
Similarly,	the	mitochondrial	toxin	rotenone	induces	ROS	production,	and	we	showed	that	it	caused	
LRRK2	activation	and	LRRK2	substrate	phosphorylation.	Interestingly,	the	rotenone-induced	activation	
of	LRRK2	was	blocked	by	inhibition	of	NOX2,	implicating	ROS-induced	ROS	release	and	NOX2-derived	
superoxide	in	the	phenomenon	(20).	To	directly	test	whether	ROS	can	activate	LRRK2,	cells	were	
treated	with	physiological	concentrations	of	H2O2,	and	this	resulted	in	increased	pSer1292	PL	signal	
and	concomitant	Rab10	phosphorylation.	These	results	suggest	that	oxidative	stress,	long	implicated	in	
PD	pathogenesis,	may	up-regulate	LRRK2	activity.	Further,	our	results	are	consistent	with	the	work	of	
Mamais	et	al.,	which	showed	that	H2O2	dissociates	LRRK2	from	14-3-3	(12),	and	the	study	by	Li	et	al.,	
which	found	a	small	activation	of	LRRK2	by	H2O2	(31).	The	molecular	mechanisms	by	which	ROS	
stimulate	LRRK2	kinase	activity	are	unknown;	whether	this	activation	results	from	direct	effects	on	the	
LRRK2	protein	or	from	effects	on	interacting	proteins,	such	as	protein	phosphatases,	remains	to	be	
explored.		
	
The	consistent	finding	that	LRRK2	is	activated	in	vulnerable	dopaminergic	neurons	in	human	iPD	raises	
the	possibility	that	LRRK2	kinase	activity	may	play	a	central	role	in	pathogenesis	of	most	PD	cases.	To	
investigate	experimentally	the	possibility	that	LRRK2	activation	may	have	downstream	deleterious	
effects	on	putative	pathogenic	mechanisms,	we	treated	rats	for	5	days	with	rotenone	–	with	or	without	
co-treatment	with	the	LRRK2	kinase	inhibitor,	PF-360.	We	found	that	rotenone	(i)	activated	LRRK2	in	
nigrostriatal	dopamine	neurons;	(ii)	increased	phosphorylation	of	a	LRRK2	substrate,	Rab10;	(iii)	
increased	levels	pSer129-α-synuclein	and	binding	to	TOM20;	and	(iv)	disrupted	markers	of	autophagy.	
All	these	effects	were	blocked	by	PF-360,	and	we	therefore	conclude	that	these	mechanisms	are	
downstream	of	LRRK2	activity	(figure	8).		
	
Rab10	is	a	bona	fide	direct	substrate	of	LRRK2	and	has	been	implicated	in	maintenance	of	endoplasmic	
reticulum,	vesicle	trafficking	and	autophagy	(32-34).	LRRK2-induced	phosphorylation	of	Rab10	inhibits	
its	function	by	preventing	binding	to	Rab	GDP-dissociation	inhibitor	factors	necessary	for	membrane	
delivery	and	recycling	(6).	Thus,	LRRK2	activation	leads	to	Rab10	phosphorylation	(and	inhibition)	and	
this	likely	impairs	autophagic	and/or	lysosomal	function.	Phospho-Rab10-induced	autophagic	
dysfunction,	in	turn,	may	account	for	the	early	accumulation	of	pSer129-α-synuclein,	which	is	normally	
degraded	by	CMA	and	macroautophagy.	Consistent	with	our	findings,	Volpicelli	and	colleagues	
reported	that	the	G2019S	mutation	was	associated	with	accumulation	of	pSer129-α-synuclein-positive	
inclusions,	which	were	prevented	by	LRRK2	kinase	inhibitors,	including	MLi-2	(35).	It	is	also	noteworthy	
that	pSer129-α-synuclein	is	one	of	the	species	of	α-synuclein	we	reported	that	binds	to	TOM20	and	
impairs	mitochondrial	function	(15).	The	fact	that	all	these	abnormalities	are	prevented	by	treatment	
with	a	LRRK2	kinase	inhibitor	strongly	supports	this	hypothetical	scheme	(figure	8).	Further,	our	
experimental	paradigm	of	surveying	potential	pathogenic	mechanisms	in	a	PD	model,	with	and	without	
concomitant	treatment	with	a	LRRK2	kinase	inhibitor,	will	likely	lead	to	new	insights	into	how	aberrant	
LRRK2	activity	causes	neurodegeneration.		
	
Our	study	is	not	without	limitations.	As	noted,	the	PL	assays	we	employed	do	not	measure	activity	per	
se;	however,	several	convergent	lines	of	evidence	confirm	that	we	measured	reliable	surrogates	of	
LRRK2	activity:	the	pS1292	PL	signal	correlated	with	substrate	(Rab10)	phosphorylation	and	with	loss	of	
14-3-3	binding	signal	–	and	both	the	1292	PL	signal	and	the	pThr72-Rab10	signal	were	inhibited	dose-
dependently	by	selective	LRRK2	kinase	inhibitors	of	different	chemical	classes.	In	this	context,	we	
provided	compelling	evidence	that	wildtype	LRRK2	is	activated	in	nigrostriatal	neurons	in	iPD	and	in	rat	
models	thereof.		Nevertheless,	while	LRRK2	activation	occurred	very	early	in	the	course	of	rotenone-
induced	parkinsonism,	and	early	intervention	with	a	LRRK2	kinase	inhibitor	was	beneficial,	the	time	
course	of	LRRK2	activation	in	the	human	brain	is	unknown	and	the	clinical	effects	of	LRRK2	inhibitors	
remain	to	be	examined.	
	
The	fact	that	there	are	a	variety	of	selective	LRRK2	kinase	inhibitors	reflects	the	interest	by	the	
pharmaceutical	industry	in	target-specific	therapeutics	for	PD,	even	for	the	relatively	small	number	of	
cases	caused	by	LRRK2	mutations.	The	results	presented	here	provide	compelling	evidence	that	WT	
LRRK2	is	activated	by	PD-relevant	relevant	stimuli	in	dopamine	neurons	in	iPD	and	that	this,	in	turn,	
triggers	a	downstream	pathological	cascade	of	events	culminating	in	neurodegeneration.	As	such,	
rather	than	being	applicable	for	3-4%	of	people	with	PD,	LRRK2-targeted	therapeutics	may	be	useful	
for	most,	if	not	all,	people	with	PD.	
	
	 	
MATERIALS	AND	METHODS	
Study	Design.	This	study	was	designed	to	assess	the	role	of	wildtype	LRRK2	in	iPD.	To	do	so,	we	
developed	new	PL	assays	to	assess	the	phosphorylation	state	of	the	LRRK2	autophosphorylation	site,	
Ser1292,	and	separately,	the	binding	of	LRRK2	to	14-3-3,	which	is	associated	with	decreased	LRRK2	
kinase	activity.	These	assays	were	validated	using	CRISPR/Cas9	genome-edited	HEK293	cells	and	3	
chemically	distinct	LRRK2	kinase	inhibitors.	The	validated	assays	were	then	used	to	assess	LRRK2	
activation	state	in	iPD	brains	and	rat	models	of	PD.	Additional	studies	examined	the	role	of	oxidative	
stress	in	activating	LRRK2,	as	well	as	downstream	consequences	of	LRRK2	activity	in	vivo.		
	
CRISPR/Cas9	Genome	Editing	of	HEK293	Cells	to	Produce	LRRK2	Knockout	and	Knock-in	Cell	Lines.	To	
generate	a	LRRK2	knockout	cell	line,	a	CRISPR/Cas9	genome	editing	approach	was	used.	A	gRNA	
targeting	exon	41	of	the	LRRK2	gene	(5’-	ATTGCAAAGATTGCTGACTAGTTTT-	3’)	was	cloned	into	the	
GeneArt	CRISPR	Nuclease	vector	(Invitrogen)	as	described	by	the	manufacturer.	HEK293	cells	were	
transfected	by	nucleoporation	using	a	Nucleoporater	II	device	(Amaxa).	Transfected	cells	were	
collected	and	enriched	by	FACS	sorting.	Sorted	cells	were	grown	and	expanded	for	PCR	and	DNA	
sequencing	analyses.	To	confirm	gene	editing	of	the	LRRK2	gene,	a	region	of	exon	41	was	PCR	amplified	
using	a	forward	primer	(5’-TTTAAGGGACAAAGTGAGCA-3’)	and	reverse	primer	(5’-
CACAATGTGATGCTTGCATTT-3’)	and	the	resulting	PCR	product	was	sequenced.	The	LRRK2	G2019S	
knock-in	cell	line	was	generated	using	a	similar	approach	but	included	transfection	of	a	120-mer	single-
stranded	oligonucleotide	containing	a	G	to	A	substitution	coding	for	a	glycine	to	serine	amino	acid	
change.	
	
A	SNCA	knockout	cell	line	was	generated	using	a	similar	approach	but	utilized	a	gRNA	targeting	exon	4	
of	the	α-synuclein	(SNCA)	gene	(5’-CTTTGTCAAAAAGGACCAGT-3’)	To	confirm	gene	editing	of	the	SNCA	
gene,	a	region	of	exon	4	was	PCR	amplified	using	a	forward	primer	(5’-	CCACCCTTTAATCTGTTGTTGC-3’)	
and	reverse	primer	(5’-	ATATAAAGGTAGCACTTTTTCACAAGG-3’)	and	the	resulting	PCR	product	was	
sequenced.	
	
Proximity	Ligation	Assay.	PLA	was	performed	as	described	previously	in	4%	PFA-fixed	tissue	or	cells	
(15).	Samples	were	incubated	with	specific	primary	antibodies	to	the	proteins	to	be	detected.	
Secondary	antibodies	conjugated	with	oligonucleotides	were	added	to	the	reaction	and	incubated.	
Ligation	solution,	consisting	of	two	oligonucleotides	and	ligase,	was	added.	In	this	assay,	the	
oligonucleotides	hybridize	to	the	two	PLA	probes	and	join	to	a	closed	loop	if	they	are	in	close	proximity.	
Amplification	solution,	consisting	of	nucleotides	and	fluorescently	labeled	oligonucleotides,	was	added	
together	with	polymerase.	The	oligonucleotide	arm	of	one	of	the	PLA	probes	acts	as	a	primer	for	
“rolling-circle	amplification”	using	the	ligated	circle	as	a	template,	and	this	generates	a	concatemeric	
product.	Fluorescently	labeled	oligonucleotides	hybridize	to	the	RCA	product.	The	PL	signal	was	visible	
as	a	distinct	fluorescent	spot	and	was	analyzed	by	confocal	microscopy	(Duolink;	Sigma	Aldrich).	
Control	experiments	included	routine	immunofluorescence	staining	of	the	proteins	of	interest	under	
identical	experimental	conditions.		
	
Statistical	analyses.	Each	result	presented	here	was	derived	from	3-6	independent	experiments.	For	
simple	comparisons	of	2	experimental	conditions,	2-tailed,	unpaired	t-tests	were	used.	Where	
variances	were	not	equal,	Welch’s	correction	was	used.	When	virus	was	injected	into	1	hemisphere	of	
the	brain	and	the	other	hemisphere	was	used	as	a	control,	2-tailed	paired	t-tests.	For	comparisons	of	
multiple	experimental	conditions,	1-way	or	2-way	ANOVA	was	used,	and	if	significant	overall,	post	hoc	
corrections	(Bonferroni	or	Sidak)	for	multiple	pairwise	comparisons	were	made.	P-values	less	than	0.05	
were	considered	significant.		
	
	
Other	methods	are	described	in	Supplemental	Materials.	
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Fig.	S1.	Active	LRRK2	is	detected	by	PL	in	microglia	in	control	brains	and	is	increased	in	iPD	and	in	
rotenone-treated	rats.	
	
Fig.	S2.	Time	course	of	in	vivo	rotenone-induced	LRRK2	activation	as	assessed	by	pS1292:LRRK2	PL	
signal.	
	
Fig.	S3.	LRRK2	is	activated	by	oligomeric	but	not	monomeric	α-synuclein.	
	
Fig.	S4.	Rotenone-induced	accumulation	of	pSer29-α-synuclein	is	LRRK2-dependent.	
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Figure	Legends	
Figure	1.	Validation	of	assays	using	CRISPR/Cas9	gene-edited	cells	and	selective	LRRK2	kinase	inhibitors.	
(A)	PL	assay	showing	LRRK2	kinase	activation	by	means	of	phosphorylation	of	the	autophosphorylation	
site,	Ser1292	(red	signal)	and	immunofluorescence	of	phosphorylation	of	the	LRRK2	substrate	Rab10	
(green	signal).	In	WT	HEK	cells	(top	row),	there	was	little	PL	signal	or	pThr73-Rab10	
immunofluorescence.	In	HEKG2019S/G2019S	cells	(2nd	row)	with	elevated	LRRK2	kinase	activity,	there	was	a	
bright	pS1292	PL	signal	and	strong	pThr73-Rab	immunofluorescence.	In	LRRK2	knockout	HEK	cells	
(bottom	row)	there	was	no	pS1292	PL	signal	and	very	little	pThr73-Rab	signal.	(B)	Quantification	of	the	
pS1292	PL	signal	in	WT,	G2019S	and	knockout	cells.	Results	reflect	3	independent	experiments.	Each	
symbol	represents	signal	from	a	single	cell.	Statistical	testing	by	ANOVA	with	post	hoc	Bonferroni	
correction.	(C)	Quantification	of	the	pThr73-Rab10	signal	in	WT,	G2019S	and	knockout	cells.	Results	
reflect	3	independent	experiments.	Each	symbol	represents	signal	from	a	single	cell.	Statistical	testing	
by	ANOVA	with	post	hoc	Bonferroni	correction.	(D)	PL	assay	of	14-3-3	binding	to	LRRK2	and	
immunofluorescence	of	Rab10	phosphorylation	at	Thr73.	In	WT	cells,	there	was	a	strong	14-3-3-LRRK2	
PL	signal	(red)	and	little	pThr73-Rab10	immunofluorescence	(green).	In	HEKG2019S/G2019S	cells,	there	was	
loss	of	14-3-3	binding	and	a	marked	increase	in	pThr73-Rab10	signal.	In	LRRK2	knockout	cells	there	was	
no	14-3-3-LRRK2	signal	and	little	pThr73-Rab10	signal.	(E)	Quantification	of	the	14-3-3-LRRK2	PL	signal	
in	WT,	G2019S	and	knockout	cells.	Results	reflect	3	independent	experiments.	Each	symbol	represents	
signal	from	a	single	cell.	Statistical	testing	by	ANOVA	with	post	hoc	Bonferroni	correction.	(F)	Dose-
response	curves	of	the	LRRK2	kinase	inhibitor	GNE-7915	against	the	pS1292	PL	signal	(filled	circles)	and	
the	pThr73-Rab10	signal	(open	circles)	in	HEKG2019S/G2019S	cells.	Cells	were	cultured	for	24	hours	with	
various	inhibitor	concentrations.	Results	from	3	independent	experiments.	Symbols	show	mean	±	SEM.	
IC50	values	calculated	by	GraphPad	Prism	software.	(G)	Dose-response	curves	of	the	LRRK2	kinase	
inhibitor	MLi-2	against	the	pS1292	PL	signal	(filled	circles)	and	the	pThr73-Rab10	signal	(open	circles)	in	
HEKG2019S/G2019S	cells.	Cells	were	cultured	for	24	hours	with	various	inhibitor	concentrations.	(H)	Dose-
response	curves	of	the	LRRK2	kinase	inhibitor	GNE-7915	against	the	pS1292	PL	signal	(filled	circles)	and	
the	pThr73-Rab10	signal	(open	circles)	in	LCLs	derived	from	an	individual	carrying	the	G2019S	mutation.	
Cells	were	cultured	for	24	hours	with	various	inhibitor	concentrations.	
	
Figure	2.	Activation	of	LRRK2	kinase	activity	in	nigrostriatal	neurons	in	iPD.	(A)	pS1292	PL	(red)	and	
pThr73-Rab10	(gray)	immunofluorescence	signals	in	sections	of	substantia	nigra	from	a	control	brain	
(top	row)	and	a	brain	from	an	individual	with	iPD	(bottom	row).	In	the	control	brain,	there	was	little	
pS1292	or	pThr73-Rab10	signal,	but	in	the	iPD	brain	there	were	strong	signals	for	both.	(B)	
Quantification	of	pS1292	PL	signal	in	8	control	brains	and	7	iPD	brains.	Statistical	comparison	by	
unpaired	2-tail	t-test.	(C)	Quantification	of	pThr73-Rab10	signal	in	8	control	brains	and	7	iPD	brains.	
Statistical	comparison	by	unpaired	2-tail	t-test.	(D)	14-3-3-LRRK2	PL	(red)	and	pThr73-Rab10	(gray)	
immunofluorescence	signals	in	sections	of	substantia	nigra	from	a	control	brain	(top	row)	and	a	brain	
from	an	individual	with	iPD	(bottom	row).	In	the	control	brain,	there	was	strong	14-3-3-LRRK2	PL	signal	
and	little	pThr73-Rab10	signal,	but	in	the	iPD	brain	the	opposite	pattern	was	seen.	(E)	Quantification	of	
14-3-3-LRRK2	PL	signal	in	8	control	brains	and	7	iPD	brains.	Statistical	comparison	by	unpaired	2-tail	t-
test.		
	
Figure	3.	Nigrostriatal	LRRK2	activation	is	reproduced	in	2	rat	models	of	PD.	(A)	pS1292	PL	and	14-3-3-
LRRK2	PL	signals	in	substantia	nigra	of	control	and	rotenone	treated	rats.	In	the	rotenone	rats,	there	
was	increased	pS1292	PL	and	loss	of	14-3-3-LRRK2	PL	signal	indicating	LRRK2	activation.	(B)	
Quantification	of	pS1292	PL	signal	in	nigrostriatal	dopamine	neurons	from	control	and	rotenone	
treated	rats.	Symbols	represent	individual	animals.	Statistical	comparison	by	unpaired	2-tail	t-test.	(C)	
Quantification	of	14-3-3-LRRK2	PL	signal	in	nigrostriatal	dopamine	neurons	from	control	and	rotenone	
treated	rats.	Symbols	represent	individual	animals.	Statistical	comparison	by	unpaired	2-tail	t-test.	(D)	
pS1292	PL	and	14-3-3-LRRK2	PL	signals	in	substantia	nigra	of	rats	that	received	a	unilateral	injection	of	
AAV2-hSNCA.	In	the	hemisphere	overexpressing	α-synuclein,	there	was	increased	pS1292	PL	and	loss	
of	14-3-3-LRRK2	PL	signal	indicating	LRRK2	activation	in	nigrostriatal	neurons.	(E)	Quantification	of	
pS1292	PL	signal	in	nigrostriatal	dopamine	neurons	from	the	control	and	AAV-hSNCA	injected	
hemispheres.	Symbols	represent	mean	values	from	each	hemisphere.	Statistical	comparison	by	paired	
2-tail	t-test.	(F)	Quantification	of	14-3-3-LRRK2	PL	signal	in	nigrostriatal	dopamine	neurons	from	the	
control	and	AAV-hSNCA	injected	hemispheres.	Symbols	represent	mean	values	from	each	hemisphere.	
Statistical	comparison	by	paired	2-tail	t-test.		
	
Figure	4.	LRRK2	is	activated	by	reactive	oxygen	species.	(A)	pS1292	PL	signal	is	increased	dose-
dependently	by	H2O2	(blue	symbols),	and	the	H2O2-induced	increase	is	blocked	by	the	antioxidant	α-
tocopherol	(5	µM)	(red	symbols).	Results	represent	3	independent	experiments.	Symbols	represent	
measurements	from	individual	cells.	Red	asterisks	=	p<0.0001	vs	no	H2O2,	ANOVA	with	Bonferroni	
correction;	blue	asterisks	=	p<0.0001	vs	H2O2	alone	at	the	same	concentration.	(B)	pThr73-Rab10	signal	
is	increased	dose-dependently	by	H2O2	(blue	symbols),	and	the	H2O2-induced	increase	is	blocked	by	the	
antioxidant	α-tocopherol	(5	µM)	(red	symbols).	Results	represent	3	independent	experiments.	Symbols	
represent	measurements	from	individual	cells.	Red	asterisks	=	p<0.0001	vs	no	H2O2,	ANOVA	with	
Bonferroni	correction;	blue	asterisks	=	p<0.0001	vs	H2O2	alone	at	the	same	concentration.	ns	=	not	
significant.	(C)	In	WT	HEK	cells	rotenone	treatment	activates	pS1292	signal	and	pThr73-Rab10	
immunoreactivity.	Both	effects	are	blocked	by	the	specific	NOX2	inhibitor	Nox2ds-tat.	(D)	
Quantification	of	the	pS1292	PL	signal	in	vehicle-	and	rotenone-treated	cells.	Results	represent	3	
independent	experiments.	Symbols	represent	measurements	from	individual	cells.	Comparison	by	
ANOVA	with	Bonferroni	correction.	(E)	Quantification	of	the	pThr73-Rab10	immunofluorescent	signal	
in	vehicle-	and	rotenone-treated	cells.	Results	represent	3	independent	experiments.	Symbols	
represent	measurements	from	individual	cells.	Comparison	by	ANOVA	with	Bonferroni	correction.	
	
Figure	5.	Nigrostriatal	LRRK2	activation	and	pSer129-α-synuclein	accumulation	can	be	blocked	in	vivo	
by	a	brain	penetrant	LRRK2	kinase	inhibitor.	(A)	pS1292	PL	and	pThr73-Rab10	signals	in	rats	treated	
with	vehicle,	PF-360	alone,	rotenone	alone	and	rotenone	+	PF-360.	(B)	Quantification	of	pS1292	PL	
signal	in	rats	treated	with	vehicle,	PF-360	alone,	rotenone	alone	and	rotenone	+	PF-360.	Symbols	
represent	individual	rats.	Comparison	by	ANOVA	with	Bonferroni	correction.	(C)	Quantification	of	
pThr73-Rab10	signal	in	rats	treated	with	vehicle,	PF-360	alone,	rotenone	alone	and	rotenone	+	PF-360.	
Symbols	represent	individual	rats.	Comparison	by	ANOVA	with	Bonferroni	correction.	(D)	pSer129-α-
Synuclein	immunoreactivity	in	rats	treated	with	vehicle,	PF-360	alone,	rotenone	alone	and	rotenone	+	
PF-360.	(E)	Quantification	of	pSer129-α-synuclein	signal	in	rats	treated	with	vehicle,	PF-360	alone,	
rotenone	alone	and	rotenone	+	PF-360.	Symbols	represent	individual	rats.	Comparison	by	ANOVA	with	
Bonferroni	correction.	
	
Figure	6.	Rotenone	induces	in	vivo	nigrostriatal	lysosomal	and	CMA	defects	that	are	prevented	by	co-
treatment	with	a	LRRK2	kinase	inhibitor.	(A)	Nigrostriatal	Lamp1	and	p62/SQSTM1	immunoreactivity	in	
rats	treated	with	vehicle,	PF-360	alone,	rotenone	alone	and	rotenone	+	PF-360.	(B)	Nigrostriatal	
Lamp2A	immunoreactivity	in	rats	treated	with	vehicle,	PF-360	alone,	rotenone	alone	and	rotenone	+	
PF-360.	(C)	Quantification	of	Lamp1	signal	in	rats	treated	with	vehicle,	PF-360	alone,	rotenone	alone	
and	rotenone	+	PF-360.	Symbols	represent	individual	rats.	Comparison	by	ANOVA	with	Bonferroni	
correction.	(D)	Quantification	of	p62/SQSTM1	signal	in	rats	treated	with	vehicle,	PF-360	alone,	
rotenone	alone	and	rotenone	+	PF-360.	Symbols	represent	individual	rats.	Comparison	by	ANOVA	with	
Bonferroni	correction.	(E)	Quantification	of	Lamp2A	signal	in	rats	treated	with	vehicle,	PF-360	alone,	
rotenone	alone	and	rotenone	+	PF-360.	Symbols	represent	individual	rats.	Comparison	by	ANOVA	with	
Bonferroni	correction.	(F)	Substantia	nigra	Lamp1	and	p62/SQSTM1	immunoreactivity	in	a	control	
brain	and	2	iPD	brains.	In	controls,	dopamine	neurons	contain	many	small	punctae	of	Lamp1	
immunoreactivity	and	very	little	detectable	p62/SQSTM1,	presumably	reflecting	efficient	autophagic	
flux.	In	iPD	brains,	note	the	marked	loss	of	Lamp1	and	accumulation	of	p62/SQSTM1	into	large	
inclusions	(Lewy	bodies)	in	dopamine	neurons	in	the	iPD	brains.	(G)	Quantification	of	Lamp1	in	control	
vs	iPD	dopamine	neurons.	Symbols	represent	individual	brains.	Comparison	by	unpaired	2-tail	t-test.	
(H)	Quantification	of	Lamp1	in	control	vs	iPD	dopamine	neurons.	Symbols	represent	individual	brains.	
Comparison	by	unpaired	2-tail	t-test.	
	
Figure	7.	Accumulated	pSer129-α-synuclein	binds	to	TOM20	in	iPD	and	this	is	replicated	in	the	
rotenone	rat	model	and	is	prevented	by	co-treatment	with	a	LRRK2	kinase	inhibitor.	(A)	pSer129-α-
synuclein-	(pS129syn)-TOM20	PL	signal	in	human	control	and	iPD	substantia	nigra	brain	sections.	(B)	
Quantification	of	the	pS129syn-TOM20	PL	signal	in	8	control	brains	and	7	iPD	brains.	Comparison	by	
unpaired	2-tail	t-test.	(C)	pS129syn-TOM20	PL	signal	and	Ndufs3	immunoreactivity	in	substantia	nigra	
of	rats	treated	with	vehicle,	PF-360	alone,	rotenone	alone	and	rotenone	+	PF-360.	In	rotenone	treated	
rats	there	is	increased	pS129syn-TOM20	PL	signal	and	reduced	levels	and	diffuse	redistribution	of	the	
nuclear	encoded	and	imported	complex	I	subunit,	Ndufs3.	These	abnormalities	were	prevented	by	
treatment	with	PF-360.	(D)	Quantification	of	the	pS129syn-TOM20	PL	signal	in	substantia	nigra	of	rats	
treated	with	vehicle,	PF-360	alone,	rotenone	alone	and	rotenone	+	PF-360.	Symbols	represent	
individual	rats.	Comparison	by	ANOVA	with	Bonferroni	correction.	(E)	Graphical	representation	of	the	
distribution	and	fluorescence	intensity	levels	of	Ndufs3	in	nigral	dopamine	neurons	in	rats	treated	with	
vehicle,	PF-360	alone,	rotenone	alone	and	rotenone	+	PF-360.	Note	the	loss	of	punctate,	high	intensity	
staining	in	the	rotenone	animals	that	is	preserved	by	co-treatment	with	PF-360.		
	Figure	8.	Activation	of	LRRK2	kinase	activity	in	iPD	and	its	downstream	consequences.	Our	data	suggest	
that	most	wildtype	endogenous	LRRK2	is	normally	in	an	inactive	state	bound	to	14-3-3	protein	
(although	the	specific	isoform(s)	of	14-3-3	have	not	been	defined	here).	ROS	signaling	activates	LRRK2	
as	indicated	by	phosphorylation	of	serine	1292	and	dissociation	from	14-3-3.	In	turn,	LRRK2	kinase	
activity	phosphorylates	Rab10	at	threonine	73	and	inhibits	its	function	by	preventing	binding	to	Rab	
GDP-dissociation	inhibitor	factors	necessary	for	membrane	delivery	and	recycling.	As	a	result,	there	is	
impairment	of	endosomal	and	lysosomal	function,	which	leads	to	accumulation	of	pSer129-α-synuclein,	
a	known	inhibitor	of	mitochondrial	protein	import.	Blockade	of	mitochondrial	protein	import	leads	to	
senescent	mitochondria	that	produce	more	ROS	that	can	feed	forward	to	amplify	this	cycle.	LRRK2	
kinase	inhibitors	block	the	downstream	effects	of	LRRK2	activation.	
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A	Central	Role	for	LRRK2	in	Idiopathic	Parkinson	Disease	
	
Summary:	Wildtype	LRRK2	is	activated	in	dopamine	neurons	in	idiopathic	Parkinson	disease	and	plays	a	
pathogenic	role	in	the	disease.	
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Materials	and	Methods	 	
	
Reagents.	Antibodies	were	sourced	as	follows:		
	
Antibody	 Cat	#	 Company	 Dilution	factor	
rabbit	Anti-LRRK2	(phospho	S1292)	
(MJFR-19-7-8)	 AB203181	 Abcam	
ICC	–	1:1000	
IHC	–	1:500	
rabbit	Anti-14	–	3	-	3	 AB9063	 Abcam	 ICC	-	1:1000	IHC	–	1:500	
mouse	Anti-Synuclein	(phospho	S129)	
[P-syn/81A]	 AB184674	 Abcam	 IHC	–	1:1000	
rabbit	Anti-LAMP1	 AB24170	 Abcam	 IHC	–	1:500	
mouse	Anti-p62/SQSTM1	 H00008878	 Abnova	 IHC	–	1:500	
rabbit	Anti-Rab10	(D36C4)	Xp(R)	 8127S	 Cell	Signaling	 ICC	–	1:1000	
GG	 goat	Anti-Rab10	pThr73	 S873D	 Dr.	Dario	Alessi	 ICC	-	1:1000	IHC	–	1:500	
rabbit	Anti-LAMP2A	 512200	 Invitrogen	 IHC	–	1:500	
mouse	Anti-Ndufs3	(OxPhos	30	KDa)	 459130	 Life	Technologies	 IHC	–	1:1000	
sheep	Anti-TH		 AB1542	 Millipore	 IHC	–	1:2000	
rabbit	Anti-TOM	20	 sc-11415	 Santa	Cruz	 IHC	-	1:1000	
mouse	Anti-LRRK2/Dardarin,		
clone	N241A/34	 75-253	
UC	Davis/	
NIH	NeuroMab	Facility	
Antibodies	incorporated	
ICC	–	1:1000	
IHC	–	1:500	
rabbit	Anti-Iba1	 019-19741	 Wako	 IHC	–	1:500	
	
Selective	LRRK2	kinase	inhibitors	were	obtained	from	the	following	sources:	GNE-7915	(ChemieTek),	
MLi-2	(Dr.	Dario	Alessi),	PF-360	(Pfizer	Inc).	
	
Fluorescence	measurements.	Quantitative	fluorescence	measurements	were	made	with	an	Olympus	
upright	3-laser	scanning	confocal	microscope,	taking	care	to	ensure	that	images	contained	no	
saturated	pixels.	For	quantitative	comparisons,	all	imaging	parameters	(e.g.,	laser	power,	exposure,	
pinhole)	were	held	constant	across	specimens.	Depending	on	the	specific	experiment,	readouts	
included	fluorescence	intensity	or	number	of	objects	(punctae)	in	predefined	regions	of	interest,	such	
as	tyrosine	hydroxylase-positive	dopaminergic	neurons	or	Iba1-positive	microglia.		
	
Animals.	All	experiments	utilizing	animals	were	approved	by	the	Institutional	Animal	Care	and	Use	
Committee	of	the	University	of	Pittsburgh.	Rats	were	treated	with	rotenone	as	described	(36,	37).	
	
AAV2-mediated	gene	transfer.	Details	per	Zharikov	et	al	(37).	Rats	were	euthanized	6	weeks	after	
injection.	
	
Human	tissue.	Paraffin-embedded	midbrain	sections	were	obtained	from	the	University	of	Pittsburgh	
Brain	Bank.	All	banked	specimens	have	undergone	standardized	premortem	neurological	and	post-
mortem	neuropathological	assessment.	Diagnoses	were	confirmed	and	staging	performed	by	the	study	
neuropathologist	(JKK)	by	examination	of	H&E,	alpha-synuclein,	tau,	silver	and	ubiquitin	stains	of	key	
sections	needed	for	Braak	staging	(38).	The	study	design	was	reviewed	and	approved	by	the	University	
of	Pittsburgh	Committee	for	Oversight	of	Research	Involving	the	Dead.	Midbrain	sections	from	7	
PD/PDD	patients	and	8	control	subjects,	matched	for	age	and	postmortem	intervals,	were	used	for	
analysis.		
	
	 Male/Female	 Age	 Brain	weight	
Postmortem	
Interval	
Control	 5/3	 67	±	5	 1248	±	33	 7.0	±	0.8	
iPD	 6/1	 73	±	4	 1297	±	29	 9.8	±	1.9	
	
To	eliminate	endogenous	fluorescence,	human	tissue	was	pre-treated	with	an	autofluorescence	
eliminating	reagent	according	to	the	manufacturer's	instructions	(Chemicon,	Temecula,	CA).	
	
	
	
	 	
		
	
	
	
Figure	S1.	Active	LRRK2	is	detected	by	PL	in	microglia	in	control	brains	and	is	increased	in	iPD	and	in	
rotenone-treated	rats.	(A)	Colocalization	of	pSer1292	PL	signal	in	Iba1	immunoreactive	microglia	in	
substantia	nigra	from	control	and	iPD	brains.	(B)	Quantification	of	pSer1292	PL	signal	in	Iba1	labeled	
microglia	in	substantia	nigra	from	8	control	and	7	iPD	brains.	Comparison	by	unpaired	2-tail	t-test.	(C)	
Colocalization	of	pSer1292	PL	signal	in	Iba1	immunoreactive	microglia	in	substantia	nigra	from	control	
and	rotenone	treated	rats.	(D)	Quantification	of	pSer1292	PL	signal	in	Iba1	labeled	microglia	in	
substantia	nigra	from	4	control	and	4	rotenone	treated	rat	brains.	Comparison	by	unpaired	2-tail	t-test.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
	
	
Figure	S2.	Time	course	of	in	vivo	rotenone-induced	LRRK2	activation	as	assessed	by	pSer1292	PL	signal.	
Note	that	LRRK2	is	significantly	activated	by	1	and	5	days	of	rotenone	treatment,	time	points	before	
there	is	detectable	neurodegeneration.	“Endpoint”,	defined	behaviorally,	typically	occurs	at	10-14	days.	
The	pSer1292	PL	signal	was	significantly	elevated	(p<0.0001,	ANOVA	with	Bonferroni	correction)	
compared	to	vehicle	at	all	time	points.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	S3.	LRRK2	is	activated	by	oligomeric	but	not	monomeric	α-synuclein.	pSer1292	PL	signal	(top	
row)	and	14-3-3:LRRK2	PL	(bottom	row)	in	SNCA-/-	cells	treated	with	vehicle,	monomeric	α-synuclein	or	
oligomeric	α-synuclein.	Note	the	increase	in	pSer1292	PL	signal	and	loss	of	14-3-3:LRRK2	–	indicating	
LRRK2	activation	–	only	in	cells	treated	with	oligomeric	α-synuclein.	The	graph	shows	quantification	of	
the	pSer1292	PL	signal	from	these	experiments	(N=3).	Each	symbol	represents	a	single	cell.	Comparison	
by	ANOVA	with	Bonferroni	correction.		
	
	 	
	
	
Figure	S4.	Rotenone-induced	accumulation	of	pSer129-α-synuclein	is	LRRK2-dependent.	Wildtype	and	
LRRK2-/-	cells	were	treated	with	rotenone	with	or	without	co-treatment	with	1	µM	PF-360.	(A)	
Representative	images	of	pSer129-α-synuclein	immunofluorescence	from	wildtype	and	LRRK2-/-	cells.	
Red,	pSer129-α-synuclein	immunofluorescence.	(B)	Quantification	of	pSer129-α-synuclein	in	wildtype	
and	LRRK2-/-	cells	24	hours	after	treatment	with	vehicle,	rotenone,	or	rotenone	+	PF-360.	Each	symbol	
represents	the	mean	value	of	an	independent	experiment	(each	with	4	technical	replicates)	in	which	
immunoreactivity	was	measured	in	at	least	80	cells.	Analysis	was	by	one-way	ANOVA	with	Sidak's	
multiple	comparisons	test.	
